{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:52:29Z","timestamp":1792115549886,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)\u2013low gastric or gastroesophageal junction (GEJ) adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with locally advanced or metastatic HER2-low (cohort 1, immunohistochemistry 2+\/in situ hybridization\u2013negative; cohort 2, immunohistochemistry 1+) gastric\/GEJ adenocarcinoma treated with at least two prior regimens, including fluoropyrimidine and platinum, but anti-HER2 therapy naive, received T-DXd 6.4 mg\/kg intravenously once every 3 weeks. The primary end point was confirmed objective response rate by independent central review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 21 patients enrolled in cohort 1 and 24 enrolled in cohort 2, 19 and 21 patients, respectively, had central HER2 confirmation, received T-DXd, and had measurable tumors at baseline. The confirmed objective response rate was 26.3% (95% CI, 9.1 to 51.2) from five partial responses in cohort 1 and 9.5% (95% CI, 1.2 to 30.4) from two partial responses in cohort 2. Thirteen patients (68.4%) in cohort 1 and 12 (60.0%) in cohort 2 experienced reduced tumor size. The median overall survival was 7.8 months (95% CI, 4.7 to nonevaluable) in cohort 1 and 8.5 months (95% CI, 4.3 to 10.9) in cohort 2; the median progression-free survival was 4.4 months (95% CI, 2.7 to 7.1) and 2.8 months (95% CI, 1.5 to 4.3), respectively. The most common grade \u2265 3 treatment-emergent adverse events in cohorts 1 and 2 were anemia (30.0% and 29.2%), decreased neutrophil count (25.0% and 29.2%), and decreased appetite (20.0% and 20.8%). Drug-related interstitial lung disease\/pneumonitis occurred in one patient in each cohort (grade 1 or 2). No drug-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This study provides preliminary evidence that T-DXd has clinical activity in patients with heavily pretreated HER2-low gastric\/GEJ adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.22.00575","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T15:59:35Z","timestamp":1668527975000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":131,"title":["Trastuzumab Deruxtecan in Anti\u2013Human Epidermal Growth Factor Receptor 2 Treatment\u2013Naive Patients With Human Epidermal Growth Factor Receptor 2\u2013Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03329690","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-5709","authenticated-orcid":false,"given":"Kensei","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-4597","authenticated-orcid":false,"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-9582","authenticated-orcid":false,"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-7553","authenticated-orcid":false,"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Frontier Science for Cancer and Chemotherapy, Osaka University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-9471","authenticated-orcid":false,"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Niigata Cancer Center Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-6165","authenticated-orcid":false,"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-703X","authenticated-orcid":false,"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaku","family":"Saito","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kamio","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kojima","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-014-0402-y"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01164-x"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30408"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4013"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"b10","volume-title":"Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing information","year":"2022"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32408"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30604-6"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02318"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30088-9"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03077"},{"key":"b18","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer, Version 4.2021","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"b19","volume-title":"Esophageal and Esophagogstric Junctions Cancers. version 4.2021","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"b20","first-page":"1","volume":"17","author":"Japanese Gastric Cancer Association","year":"2020","journal-title":"Gastric Cancer"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30739-3"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1004"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30328-6"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4560"},{"key":"b25","volume":"32","author":"Van Cutsem E","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.00575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T18:03:59Z","timestamp":1674842639000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.00575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1200\/JCO.22.00575"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.00575","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"2022-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}